Back to Dashboard
NUVL · Healthcare

Nuvalent Inc

USA Healthcare Filing: 2026-06-30
30/100
Smart-money confidence
Below average interest

No standout activity across the feeds we track.

Stocks scoring 25–45 beat the S&P 500 45.3% of the time over the next three months, since 2015. How we measured this →

8
hedge funds
hold it · 3 new, 3 added, 2 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$9.8B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About NUVALENT INC

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib…

Who's behind the signal
Every informed buyer we can see on NUVL, across all three feeds.
Hedge funds · 8
Point72 (Steve Cohen) New position
D.E. Shaw & Co New position
Renaissance Technologies Increased +216%
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. NUVALENT INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
3
New positions
3
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to reset Pinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to NUVALENT INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NUVALENT INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime · Privacy